Skip to main content
Contact Us
Subscribe
E-Edition
62°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
375.50
+0.21 (+0.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
Next >
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
July 08, 2023
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic...
Via
Talk Markets
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
June 27, 2023
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or...
Via
Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
June 26, 2023
The European Union has reco
Via
Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
June 21, 2023
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 20, 2023
Via
Benzinga
The Latest Analyst Ratings for argenx
June 07, 2023
Via
Benzinga
Analyst Expectations for argenx's Future
June 07, 2023
Via
Benzinga
Expert Ratings for argenx
May 31, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
May 31, 2023
Via
Benzinga
Booking Holdings To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
May 05, 2023
Wells Fargo raised the price target for Royal Caribbean Cruises Ltd. (NYSE: RCL) from $78 to $88. Wells Fargo analyst Daniel Politzer maintained an Overweight rating. Royal Caribbean Cruises shares...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
April 25, 2023
Via
Benzinga
Analyst Ratings for argenx
April 21, 2023
Via
Benzinga
A Bearish Sign Appears On argenx's Chart
March 23, 2023
Via
Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
April 12, 2023
Via
Benzinga
Analyst Ratings for argenx
March 20, 2023
Via
Benzinga
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
March 20, 2023
Via
Benzinga
5 Analysts Have This to Say About argenx
March 03, 2023
Via
Benzinga
Earnings Outlook For argenx
March 01, 2023
Via
Benzinga
Immunovant Could Potentially Be An M&A Target, Writes Analyst
February 15, 2023
Via
Benzinga
Analyst Ratings for argenx
January 10, 2023
Via
Benzinga
Analyst Ratings for argenx
December 07, 2022
Via
Benzinga
Expert Ratings for argenx
December 07, 2022
Via
Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
January 10, 2023
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in...
Via
Benzinga
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
December 22, 2022
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading.
Via
Benzinga
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
November 30, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review
November 22, 2022
Via
Benzinga
McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
October 28, 2022
Wedbush raised McDonald's Corporation (NYSE: MCD) price target from $265 to $300. Wedbush analyst Nick Setyan maintained the stock with an Outperform rating. McDonald's shares rose 3.3% to close at...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.